Serbia plans to start laboratory testing of Russia's Sputnik V vaccine against the coronavirus and it will also continue talks with drugmaker Pfizer Inc about purchasing its shot, the country's prime ...

Pfizer Inc said on Wednesday it had offered to provide Brazil with millions of doses of a COVID-19 vaccine in the first half of 2021, amid evidence the coronavirus is spreading more rapidly in South ...

Collegeville’s Bridge at Collegeville campus, home to Pfizer and Dow, sees a 75 percent tax cut as owners plan major life ...

The solvent dichloromethane, or DCM, is commonly used to strip paint and cut grease. It's also what generations of chemistry ...

K-State opened a brand new biomanufacturing lab in Seaton Hall last week. Vice president of research Beth Montelone was a ...

A pair of pharmaceutical giants spearheaded gains for other stocks in the industry on Tuesday, Sept. 30, 2025, while a new OpenAI partnership weighed on payments providers.

LYS Labs, the Web 3.0 data infrastructure company building the intelligence layer for machine finance on Solana, today announced a series of significant milestones that underscore its rapid growth and ...

Shares of Metsera Inc. were rocketing into record territory in early Monday trading after the developer of obesity treatments announced an agreement to be acquired by Pfizer Inc. in a deal with an ...

Pfizer will acquire Metsera in a deal worth $4.9 billion up front and up to $7.3 billion if the acquired assets succeed further. Metsera is developing anti-obesity treatments that could differentiate ...

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. 13 states that don’t tax your ...

The last time I spoke about Metsera, Inc. (NASDAQ:MTSR), it was in a Seeking Alpha article entitled "Metsera: Capturing of Obesity Market With Long-Acting GLP-1 Differentiation." With respect to this ...

Pfizer is reportedly nearing a $7.3 billion acquisition of Metsera, a weight-loss drug developer. The deal is expected to include $47.50 per share, with an additional contingent payment based on ...